Stock MEDCL MEDINCELL S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights MedinCell S.A.

Equities

MEDCL

FR0004065605

Real-time Euronext Paris
Other stock markets
 03:52:59 2024-06-12 am EDT 		5-day change 1st Jan Change
14.66 EUR -0.68% Intraday chart for MedinCell S.A. -6.27% +103.61%
Jun. 10 Transcript : MedinCell S.A., 2024 Earnings Call, Jun 10, 2024
Jun. 10 Medincell: a 'new era' after a 'pivotal' 2023 CF

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Medincell: a 'new era' after a 'pivotal' 2023
CF
Medincell: share price falls after disappointing clinical study
CF
Medincell Provides Update on Phase 3 mdc-CWM Clinical Trial
CI
Medincell: share price rises on resumption of trading
CF
CAC40: remains in green in a neglected market
CF
Medincell: positive results in schizophrenia
CF
Medincell Listing Temporarily Suspended on Euronext Paris
MT
Teva and Medincell's schizophrenia drug meets main goal of late-stage study
RE
Teva Pharmaceuticals and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-?749 as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia
CI
Medincell: share price rises following agreement with AbbVie
CF
Medincell, AbbVie to Co-Develop Injectable Therapeutics
DJ
Medincell Enters Into Strategic Co-development and Licensing Agreement with AbbVie to Develop Next-generation Long-acting Injectable Therapies
CI
Medincell: Unitaid grant to combat malaria
CF
Medincell Receives $6 Million Extension Grant from Unitaid for Malaria Drug Trial
MT
Medincell S.A. Reaches Commercial Stage with the Market Launch by Teva of Uzedy? for the Treatment of Schizophrenia
CI
Teva Pharmaceutical Industries Ltd. Announces Recruitment Completion of Phase 3 Clinical Study of mdc-TJK / Olanzapine Long-Acting Injectable
CI
MedinCell: first-half net loss reduced
CF
MedinCell S.A. Reports Earnings Results for the Half Year Ended September 30, 2023
CI
Medincell Announces Successful Completion of Patient Enrollment in the Phase 3 Study of F14 (Mdc-Cwm), A First-In-Class Therapy for Localized Pain Relief After Total Knee Replacement
CI
MedinCell S.A. Reports Earnings Results for the Full Year Ended March 31, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MEDCL Stock
  4. News MedinCell S.A.
  5. Highlights